Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2

Manuela Di Fusco, Mary M Moran, Alejandro Cane, Daniel Curcio, Farid Khan, Deepa Malhotra, Andy Surinach, Amanda Miles, David Swerdlow, John M McLaughlin, Jennifer L Nguyen
doi: https://doi.org/10.1101/2021.10.12.21264707

Article Information

doi 
https://doi.org/10.1101/2021.10.12.21264707
History 
  • October 16, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Manuela Di Fusco1,*,
  2. Mary M Moran2,
  3. Alejandro Cane1,
  4. Daniel Curcio1,
  5. Farid Khan2,
  6. Deepa Malhotra1,
  7. Andy Surinach3,
  8. Amanda Miles1,
  9. David Swerdlow2,
  10. John M McLaughlin2 and
  11. Jennifer L Nguyen1
  1. 1Pfizer Inc., New York, NY USA
  2. 2Pfizer Inc., Collegeville, PA, USA
  3. 3Genesis Research, Hoboken, NJ, USA
  1. ↵*Corresponding author
    Manuela Di Fusco, Patient and Health Impact, Health Economics and Outcomes Research, Pfizer, Inc., New York, NY, USA, Manuela.difusco{at}pfizer.com
Back to top
Posted October 16, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2
Manuela Di Fusco, Mary M Moran, Alejandro Cane, Daniel Curcio, Farid Khan, Deepa Malhotra, Andy Surinach, Amanda Miles, David Swerdlow, John M McLaughlin, Jennifer L Nguyen
medRxiv 2021.10.12.21264707; doi: https://doi.org/10.1101/2021.10.12.21264707
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area